Business
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026 REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the
About this update from Purple Biotech Ltd.
[{"type":"image","alt":"Purple Biotech Ltd.","displaySize":"","headline":null,"caption":"Purple Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":250,"url":"https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/b_q3OJwHS.6FpUIZPiP7Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5","width":300,"height":250}},"lazy":false},{"type":"text","content":"IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator","length":123,"tagName":"p"},{"type":"text","content":"IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design","length":170,"tagName":"p"},{"type":"text","content":"IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026","length":118,"tagName":"p"},{"type":"text","content":"REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced successful completion of a non-human primates toxicology study (the “Study”) of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen expressed on multiple solid tumors.","length":505,"tagName":"p"},{"type":"text","content":"The Study demonstrated that IM1240's proprietary capping technology enabled dosing at levels up to 300-fold higher than a non-capped comparator, with significantly reduced immune-related toxicity, including minimal cytokine release. These results highlight the unique safety profile of this approach, which may address a key limitation of certain current T cell engagers, where cytokine release syndrome can restrict dosing.","length":428,"tagName":"p"},{"type":"text","content":"“In the Study, IM1240 demonstrated a favorable safety and tolerability profile, with hematologic findings that align with its expected pharmacodynamic effects on immune activation. The CD3 capping design of IM1240 sh...